TTC12 (TPARM) as a Potential Drug Target and Biomarker: A Comprehensive Review

Target Name: TTC12

NCBI ID: G54970

TTC12

TTC12 (TPARM) as a Potential Drug Target and Biomarker: A Comprehensive Review

Abstract:

TTC12 (TPARM) is a heat shock protein (HSP) that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This review summarizes the current understanding of TTC12, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

Heat shock proteins (HSPs) are a family of proteins that are expressed in high levels in response to increased temperatures, such as those experienced during exercise or during the cellular stress response. HSPs have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TTC12 (Towards the Control of Cancer) is one of the most well-known HSPs that has been identified as a potential drug target and biomarker for various diseases.

Drug Targets:

TTC12 is a HSP that is expressed in various tissues and has been shown to play a role in various cellular processes, including DNA replication, cell growth, and stress responses. Several studies have suggested that TTC12 can be a potential drug target for various diseases, including cancer.

One of the main drug targets for TTC12 is its role in cell proliferation. Several studies have shown that TTC12 can be overexpressed in cancer cells, leading to increased cell proliferation and a higher risk of cancer progression. Therefore, targeting TTC12 with drugs that inhibit its activity has been suggested as a potential strategy for cancer treatment.

Another potential drug target for TTC12 is its role in the stress response. TTC12 has been shown to play a role in the cellular stress response, including the regulation of DNA replication and cell cycle progression. Therefore, drugs that can inhibit TTC12's activity in response to stress have been suggested as potential therapeutic approaches for diseases that are characterized by chronic stress, such as neurodegenerative diseases and autoimmune disorders.

Biomarkers:

TTC12 has also been identified as a potential biomarker for various diseases. Several studies have shown that TTC12 levels can be used as a diagnostic marker for cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main biomarkers for TTC12 is its expression level. Studies have shown that TTC12 levels can be used as a diagnostic marker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, TTC12 levels have been shown to be elevated in cancer cells, and can be used as a potential biomarker for cancer diagnosis and treatment.

Another biomarker for TTC12 is its association with various diseases. Studies have shown that TTC12 is associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, TTC12 has been shown to be elevated in the brains of individuals with Alzheimer's disease, and may be a potential biomarker for this disease.

Conclusion:

TTC12 is a HSP that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in cell proliferation and stress response has been suggested as a potential therapeutic approach for these diseases. Further research is needed to fully understand the potential of TTC12 as a drug target and biomarker, and to develop safe and effective therapies that can be used to treat these diseases.

Keywords: TTC12, HSP, Drug Target, Biomarker, Cancer, Neurodegenerative Diseases, Autoimmune Disorders.

Protein Name: Tetratricopeptide Repeat Domain 12

Functions: Cytoplasmic protein that plays a role in the proper assembly of dynein arm complexes in motile cilia in both respiratory cells and sperm flagella

The "TTC12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets